FRAMINGHAM, Mass. and SYDNEY, Jan. 6 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN), a leading innovator and provider of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that it is scheduled to make an investor presentation at the 28th Annual J.P. Morgan Healthcare Conference at 3:00 pm PST on Wednesday, January 13. The conference will be held January 11-14 at the Westin St. Francis Hotel in San Francisco.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com. An archived replay of the presentation will also be available shortly after the presentation time for a period of 90 days.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or left ventricular assist devices, to treat Class IIIb and Class IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD(TM) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare® Ventricular Assist System in the European Union. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication. 


    For further information:
    ------------------------
    Christopher Taylor
    HeartWare, Inc.
    ctaylor@heartwareinc.com
    Tel: +1 508 739 0950

    Matt Clawson
    Allen & Caron Inc
    matt@allencaron.com
    Tel: +1 949 474 4300

SOURCE HeartWare International, Inc.